Navigation Links
Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
Date:12/22/2011

WALTHAM, Mass., Dec. 22, 2011 /PRNewswire/ -- Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing of an $8 million financing arrangement with Alopexx Enterprises, LLC for the continued development of anti-cancer therapeutic, DI-Leu16-IL2.

DI-Leu16-IL2 is among a class of molecules called immunocytokines that are being developed for the treatment of various forms of cancer.  Immunocytokines, combine the immune stimulating features of cytokines with the targeting properties of antibodies. DI-Leu16-IL2, Provenance's most advanced program, is a de-immunized form of an anti-CD20 antibody, Leu16, genetically fused to the cytokine, interleukin 2 (IL2). DI-Leu16-IL2 is being studied for the treatment of non-Hodgkin's lymphoma and other forms of hematological cancer and is currently in an investigator sponsored Phase I clinical trial.

Under the terms of the financing, Provenance and Alopexx Enterprises, LLC have formed a new company, Alopexx Oncology, LLC to manage the clinical development of DI-Leu16-IL2. Financial details of the transaction are not disclosed.

About Provenance Biopharmaceuticals Corp.

Provenance is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and other serious, life-threatening diseases. The Company's engineered antibody technologies promote the body's own immune system to recognize and fight disease. In addition to DI-Leu16-IL2, Provenance has several additional early-stage molecules in development. For more information, please go to http://www.provenancebio.com.

About Alopexx Enterprises, LLC.

Alopexx Enterprises, LLC is a healthcare company focused on acquiring and developing preclinical and early clinical compounds, with an emphasis on infectious diseases, oncology, and CNS.  It was founded in 2011 by highly experienced pharmaceutical executives and leverages the unique insights and experiences of its founders and world-class scientific advisors. Beyond the financial investment the group is able to offer hands-on expertise in pre-clinical development, manufacturing, regulatory affairs, logistics, clinical development and partnering.  For more information please go to www.alopexx.com.


'/>"/>
SOURCE Provenance Biopharmaceuticals Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
2. Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting
3. Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)
4. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
5. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
10. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
11. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):